The Social and Medical Aspects of Drug Abuse. Written by Charles P O'Brien
|
|
- Roderick Stafford
- 7 years ago
- Views:
Transcription
1 The work of Abraham Wikler (1973) over the past three decades has called attention to the importance of conditioned responses in the addictive process. Drugs act as powerful forces in shaping behavior, both by their direct pleasant effects (positive reinforcement) and by their effects in relieving withdrawal symptoms (negative reinforcement). Wikler theorized that the environmental cues which have been repeatedly paired with drug-induced states may become conditioned stimuli. He observed that former addicts who are free of drugs often develop tearing and yawning (opiate withdrawal signs) when they discuss drugs in group therapy. He and others subsequently showed that withdrawal signs could become conditioned in animals (Wikler and Pescor, 1967; Goldberg and Schuster, 1970). More recently, conditioned withdrawal has been demonstrated in humans (O'Brien et al, 1975; O'Brien et al, 1977). These conditioned withdrawal responses are thought to be partly due to simple pairing of pharmacological withdrawal with environmental cues, and partly due to pairing of environmental stimuli with the body's homeostatic mechanisms adapting to the onset of drug effects (Wikler, 1973; Siegel, 1974). Eventually the environmental stimuli themselves can elicit the adaptative response and this can be perceived as withdrawal. As a result of this conditioning former addicts may develop withdrawal symptoms when they return to the environment in which they had previously used drugs. Not only do they develop drug-craving, but actual physical signs of sickness may occur (tearing, yawning, nausea, vomiting). There is also some evidence (Whitehead, 1974; O'Brien, 1975) that conditioned withdrawal can occur in patients maintained on a steady dose of methadone. There are other conditioning factors which help to maintain self-administration of drugs. Addicts tend to use drugs in a ritualistic fashion. When the drug is administered, the withdrawal discomfort (both pharmacological and conditioned) is eased. At times, depending on the level of tolerance and dose of the drug used, the patient will feel euphoric. There is some controversy over how often a typical addict obtains euphoria rather than just relief of withdrawal distress (McAulliffee and Gordon, 1974), but clearly the reward is intermittant. Since intermittant reinforcement is very effective in maintaining behavior, this may explain why self-administration can continue when street heroin potency is low or when saline is substituted for opiate (O'Brien, 1975). Addicts who report pleasure from self-injection of inactive substances have been termed "needle freaks" (Levine, 1974). This phenomenon is usually seen only in "blind" conditions when the user expects a drug effect, but the substance administered actually contains little or no active drug. If addicts are informed that a substance is a placebo or if they know they are on an antagonist which will block drug effects, self-injection will stop after a few trials (Altman et al, 1976). The existence of these conditioned phenomena requires that they be considered in the treatment of addiction. A number of innovative methods have been attempted which might influence conditioning or enable the patient to cope with conditioned withdrawal or conditioned drug craving. 1 / 7
2 COUNTERCONDITIONING PROCEDURES Numerous published studies have described procedures to combat drug-taking behavior by aversive conditioning. These have been critically reviewed by Callner (1975). The reports consist of single cases or groups of cases, some with excellent results. Electrical and chemical aversion techniques are difficult to apply to typical addicts, and the method of covert conditioning (Cautela, 1975) has gained some acceptance. Covert conditioning or sensitization consists of the use of imagined scenes as aversive events and as rewarding events. Beginning with the initial craving for drugs the patient is asked to imagine as clearly as possible each link in the chain of events leading to drug-taking. Instead of pleasant drug effects, the patient is asked to imagine becoming severely ill in vivid terms as a consequence of the drug. When the patient imagines the avoidance of drugs he is told to imagine pleasant scenes. Covert sensitization has been successfully used in several published case reports or series of cases (Wisocki, 1973; Cautela and Rosenstein, 1975). It has been used in combination with other behavioral techniques (O'Brien et al, 1972) and it has been successfully augmented by hypnosis (Copeman, 1977) and by chemical aversion (Maletzky, 1974). EXTINCTION OR DESENSITIZATION PROCEDURES One approach to treatment is to attempt the systematic extinction of conditioned responses which have developed throughout the course of addiction. This method directly follows from the assumption that conditioned responses are helping to maintain drug-taking behavior. Thus an attempt to extinguish these responses would appear logical. To accomplish this, exposure to the situations associated with drug-taking should be accomplished, but drug effects must not follow. Kraft (1970) in a series of case reports of amphetamine-barbiturate users found certain social situations to provoke drug-taking. His treatment consisted of setting up hierarchies of such situations for each patient (Wolpe, 1958) and exposing the patient to each one beginning with the least evocative situation. Hypnosis and relaxation were used to prevent the patient from responding in the usual way with anxiety and drug-ingestion. Although definition of population and follow-up were minimal (Kraft, 1976), the results were encouraging. 2 / 7
3 Our group (O'Brien, 1975) has been able to obtain (by behavioral interview) hierarchies of stimuli which provoke craving or withdrawal responses among addicts. When slides or video tapes of these situations were shown to addict patients, the response was variable. Some reported strong drug-craving and others reported no effects (O'Brien et al, 1974). In subsequent studies we have thus far failed to find stimuli which are consistently effective. Negative affectual responses and slight feelings of withdrawal have been reported by Tea'sdale (4973) when drug related slides were shown to addicts. Physiological changes in response to video tapes of drug taking behavior have been reported by Sideroff and Jarvik (1977). We have conducted several studies of detoxified opiate addicts and control subjects under baseline conditions in a controlled environment. While some addicts showed conditioned withdrawal responses to slides and video tapes of drug-related activities, more consistent responses occurred when the subjects handled bags of heroin or went through pre-injection rituals ("cook-up"). Conditioned withdrawal responses were: decreases in skin temperature, increases in heart rate, increases in pupil size, and increased scores on withdrawal and craving ratings (O'Brien et al, Note 1). If a simple technique could be found for producing conditioned craving or withdrawal in the clinic, patients could be systematically desensitized. Of course, it is not certain how much generalization there would be to the natural environment. For optimum effectiveness, it might be necessary for patients to be desensitized in situations that clearly resemble their own neighborhoods. Narcotic antagonists have also been considered as an aid to extinction of drug conditioned responses (Wikler, 1974). While a patient is receiving an antagonist, such as naltrexone, he is effectively "protected" from most of the effects of injected opiates. Thus he can be exposed to stimuli which provoke opiate use and even use opiates with little or no reinforcement. However, most patients who are maintained on narcotic antagonists rarely test them by injecting heroin. This is confirmed by urine tests as well as by patients reports (Kleber et al, 1974; O'Brien et al, 1974). The patients report that once they are convinced that opiate effects will be blocked by the antagonist, they do not wish to waste their money by using heroin. Since the addicts do not perform the rituals which usually precede drug-taking, they do not actually extinguish the conditioned responses associated with this behavior. Another problem is that duration of treatment with naltrexone is usually fairly brief (National Research Council, 1978) and thus opportunities for extinction are limited. The antagonist is lacking in the reinforcing properties found in agonist such as methadone. It produces no euphoria and no physical dependence. In the absence of pharmacological reinforcement, small monetary rewards have been recommended to induce patients to continue ingesting naltrexone (Meyer et al, 1976). We have found the scheduling of the monetary reward to be important (Grabowski et al, 1978, Note 2). Both response-based schedules (continuous reinforcement, 3 / 7
4 fixed ratio, variable ratio) and a time-based schedule (fixed interval) were compared. The contingency payments (a total of $40 per month for all schedules) produced a significant lengthening of duration of naltrexone treatment. The fixed ratio condition ($3.34 every third visit) was found to be optimal. Although the contingency payments produced a clear effect on treatment duration, our preliminary follow-up data suggest that active extinction,of conditioned responses is necessary to improve overall treatment success rate. How can former addicts be induced to go through pre-injection rituals while protected by naltrexone? Meyer et al (1976) have reported that hospitalized former addicts on naltrexone usually did not continue to inject heroin spontaneously even when the drug is readily available at minimal cost. They did resume injecting when naltrexone was stopped. Our group (O'Brien et al, 1974; O'Brien, 1975) has attempted to actively extinguish pre-injection rituals and self-injection behavior as an experimental treatment. Former addicts maintained on antagonist (cyclazocine or naltrexone) were given opiates to self-inject on a regular prescribed basis in the laboratory. The behavior of these addicts changed remarkably over 5 to 25 self-injections and this occurred whether the injections contained saline or opiate (double-blind). The entire procedure (including pre- and post-injection rituals) was reported as mildly pleasant after the first several injections. The pre-injection rituals themselves produced craving and withdrawal as measured by rating scales and physiological responses. The injection itself relieved withdrawal and produced weak opioid effects on the first several occasions. As extinction progressed, the withdrawal responses increased and were worsened rather than relieved by the self-injection. Some patients became angry and many refused to continue the injections despite cash inducements. Although the blocked self-injections resulted in the patients' no longer enjoying the drug-taking rituals, it was found that long-term outcome did not appear to have been affected. Recently, however, we have analyzed data from 118 patients who were followed-up at one month and six months after stopping naltrexone (O'Brien et al, Note 3). Ninety-seven patients received naltrexone and no behavioral treatment. Twenty-one were randomly assigned to self-injection ("extinction") using either an opiate (hydromorphone) or saline under double-blind conditions. There were no significant differences among treatment groups in age, education, sex, duration of addiction, criminal involvement, or prior treatment history. All patients received supportive counseling during treatment. The duration of treatment was approximately 60 days for all treatment groups except for those who self-injected saline. The saline group more rapidly developed craving and withdrawal responses and dropped out of treatment after a mean of only 31 days. Six months after stopping treatment, approximately 84 percent of patients were located for a follow-up interview, and urine test. Outcome was determined by employment, drug use, criminal activity, and social functioning measures. Patients who self-injected opiate in the laboratory while "blocked" by naltrexone had a significantly better outcome than controls who received no behavior therapy. Those who received saline had a significantly worse outcome than controls. 4 / 7
5 These results are only preliminary; they must be replicated by a larger study which eliminates some of the flaws in the initial study. The data suggest, however, that attempts to extinguish putative conditioned responses in opiate addicts can have beneficial effects or detrimental effects depending on how extinction procedures are applied. We are now testing a more gradual desensitization procedure which may lead to longer treatment duration and better outcome. CONCLUSION There is considerable evidence from animal and human studies that conditioning plays a role in maintaining drug-seeking behavior. Systematic efforts to modify drug conditioned bheavior as a therapeutic modality are still in their early stages. Although the initial results are promising, it must be remembered that human drug addiction is a complex process involving political and social as well as psychological and pharmacological factors. Behavioral treatments must be accompanied by broad rehabilitative measures. NOTES 1. O'Brien CP, Ternes J and Greenstein R: Conditioned responses to drug-related stimuli in addicts and former addicts. (Manuscript in preparation) 2. Grabowski J, O'Brien CP, Greenstein R, Long M, Steinberg-Donato, S and Ternes J: Effects of contingent payment on compliance with a naltrexone regiman. (Manuscript in preparation) 3. O'Brien CP, Greenstein R, McLellan T, Ternes J and Woody G: Follow-up of opiate addicts treated by naltrexone and extinction of conditioned responses. (Manuscript in preparation) REFERENCES 5 / 7
6 Altman JL, Meyer RE, Mirin SM and McNamee HB: Opiate antagonists and the modification of heroin self-administration behavior in man. Int J Addiction 11(3): ,1976 Caliner DA: Behavioral treatment approaches to drug abuse: A critical review of the research. Psycho! Bull 82: , 1975 Cautela JR and Rosenstein AK: The use of covert conditioning in the treatment of drug abuse. Int J Addiction 10: , 1975 Copemann CD: Treatment of polydrug abuse and addiction by covert sensitization: Some contraindications. Int J Addictions 12:17-23, 1977 Goldberg SR and Schuster CR: Conditioned nalorphine-induced abstinence changes; persistence in post-morphine dependent monkeys. J Exper Anal Behav 14:33-46, 1970 Kleber H, Kinsella JK, Riordan C, Greaves S and Sweney D: The use of cyclozocine in treating narcotic addicts in a low-intervention setting. Arch Gen Psychiatry 30:37-42, 1974 Kraft T: Treatment of drinamyl addiction. J Nery Ment Disorder 150: ,1970 Kraft T: Long-term effects of behavior therapy. Br J Psychiatry , 1976 Lal H, Miksic S and Smith N: Naloxone antagonism of conditioned hyperthermia: An evidence for release of endogenous opioid. Life Science 18: , 1976 Levine, DG: Needle freaks: Compulsive self-injection by drug users. Am J Psychiatry 131: , 1974 Maletzky BM: Assisted covert sensitization for drug abuse. Int J Addictions 9: , 1974 McAulliffee WE and Gordon RA: A test of Lindesmith's theory of addiction: The frequency of euphoria among long-term addicts. Am J Sociol 79: , 1974 Meyer R, Randall M, Barrington C, Mirin S and Greenberg I: Limitations of an extinction approach to narcotic antagonist treatment. Nat Inst Drug Abuse, Res Mon Series (9): , 1976 National Research Committee: Clinical evaluation of naltrexone treatment of opiate dependent individuals. Arch Gen Psychiatry 35: , 1978 O'Brien CP: Experimental analysis of conditioning factors in human narcotic addiction. Pharmacl Rev 27: , 1975 O'Brien CP, Chaddock B, Woody G and Greenstein R: Systematic extinction of narcotic drug use using narcotic antagonists. Pro NAS/NRC Corn Probl Drug Depend , Washington, D.C., 1974 O'Brien CP, O'Brien TJ, Mintz J and Brady JP: Conditioning of narcotic abstinence symptoms 6 / 7
7 in human subjects. Drug Alco Depend , 1975 O'Brien CP, Testa T, O'Brien TJ, Brady JP and Wells B: Narcotic withdrawal in humans. Science 195: , 1977 O'Brien JS, Raynes AE and Patch VD: Treatment of heroin addiction with aversion therapy relaxation training and systematic desitization. Behav Res Ther 10:77-80, 1972 Sideroff SI and Jarvik ME: Conditioned responses to a video tape showing heroin related stimuli. Pro Nat Drug Con Drug Abuse May 5-9, 1977, (in press) Siegal S: Evidence from rats that morphine tolerance is a learned response. J Compar Physiol Psych 89(5): , 1975 Teasdale JD: Conditioned abstinence in narcotic addicts. Int J Addictions 8: , 1974 Whitehead C: Methadone pseudowithdrawal syndrome: Paradign for a psychopharmacological model of opiate addiction. Psychosom Med 35: , 1974 Wikler A: Dynamics of drug dependence. Arch General Psychiatry 28: , 1973 Wikler A: Conditioning of successive adaptive responses to the initial effects of drugs. Conditional Reflex 8: , 1973 Wikler A: Requirements for extinction of relapse-facilitating variables and for rehabilitation in a narcotic antagonist treatment program. In: Narcotic Antagonists, MC Braude, et al (eds), New York: Raven Press, , 1974 Wikler A and Prescor F: Classical conditioning of a morphine abstinence phenomenon, reinforcement of opioid-drinking behavior and "relapse" in morphine-addicted rats. Psychopharmacologia 10: , 1967 Wisocki PA: The successful treatment of a heroin addict by covert conditioning techniques. J Behav Ther Experi Psychiatry 4:55-61, 1973 Wolpe J: Psychotherapy by Reciprocal Inhibition, pp Stanford, California: Stanford University Press, / 7
Tolerance and Dependence
Tolerance and Dependence Drug Tolerance is a decrease in the effect of a drug as a consequence of repeated exposure. Change over repeated exposures. Different effects may show different tolerance. Tolerance
More informationNeurobiology and Treatment of Opioid Dependence. Nebraska MAT Training September 29, 2011
Neurobiology and Treatment of Opioid Dependence Nebraska MAT Training September 29, 2011 Top 5 primary illegal drugs for persons age 18 29 entering treatment, % 30 25 20 15 10 Heroin or Prescription Opioids
More informationUsing Drugs to Treat Drug Addiction How it works and why it makes sense
Using Drugs to Treat Drug Addiction How it works and why it makes sense Jeff Baxter, MD University of Massachusetts Medical School May 17, 2011 Objectives Biological basis of addiction Is addiction a chronic
More informationNaltrexone and Alcoholism Treatment Test
Naltrexone and Alcoholism Treatment Test Following your reading of the course material found in TIP No. 28. Please read the following statements and indicate the correct answer on the answer sheet. A score
More informationA HISTORICAL PERSPECTIVE ON HUMAN ABUSE LIABILITY STUDIES. Donald R Jasinski, MD
A HISTORICAL PERSPECTIVE ON HUMAN ABUSE LIABILITY STUDIES Donald R Jasinski, MD Origin of methods Modify morphine molecule Develop a selective analgesic lacking abuse potential Reduce public health and
More informationTreatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call 1-800-662-HELP(4357)
More informationDrugFacts: Treatment Approaches for Drug Addiction
DrugFacts: Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please
More informationTreatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction [NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call
More informationTreatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone )
Treatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone ) Elinore F. McCance-Katz, M.D., Ph.D. Professor and Chair, Addiction Psychiatry Virginia Commonwealth University Neurobiology of Opiate
More informationTreatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call the
More informationUpdate on Buprenorphine: Induction and Ongoing Care
Update on Buprenorphine: Induction and Ongoing Care Elizabeth F. Howell, M.D., DFAPA, FASAM Department of Psychiatry, University of Utah School of Medicine North Carolina Addiction Medicine Conference
More informationMinimum Insurance Benefits for Patients with Opioid Use Disorder The Opioid Use Disorder Epidemic: The Evidence for Opioid Treatment:
Minimum Insurance Benefits for Patients with Opioid Use Disorder By David Kan, MD and Tauheed Zaman, MD Adopted by the California Society of Addiction Medicine Committee on Opioids and the California Society
More informationTENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION
TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION The Tennessee Board of Medical Examiners has reviewed the Model Policy Guidelines for Opioid Addiction Treatment
More informationIntegrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings
Integrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings All-Ohio Conference 3/27/2015 Christina M. Delos Reyes, MD Medical Consultant,
More informationThe Results of a Pilot of Vivitrol: A Medication Assisted Treatment for Alcohol and Opioid Addiction
The Results of a Pilot of Vivitrol: A Medication Assisted Treatment for Alcohol and Opioid Addiction James H. Barger, MD SAPC Medical Director and Science Officer Desiree A. Crevecoeur-MacPhail, Ph.D.
More informationDeveloping Medications to Treat Addiction: Implications for Policy and Practice. Nora D. Volkow, M.D. Director National Institute on Drug Abuse
Developing Medications to Treat Addiction: Implications for Policy and Practice Nora D. Volkow, M.D. Director National Institute on Drug Abuse Medications Currently Available For Nicotine Addiction Nicotine
More informationDependence and Addiction. Marek C. Chawarski, Ph.D. Yale University David Metzger, Ph.D. University of Pennsylvania
Dependence and Addiction Marek C. Chawarski, Ph.D. Yale University David Metzger, Ph.D. University of Pennsylvania Overview Heroin and other opiates The disease of heroin addiction or dependence Effective
More informationMedication Assisted Treatment. Ned Presnall, MSW, LCSW May 17, 2014
Medication Assisted Treatment Ned Presnall, MSW, LCSW May 17, 2014 FRONTAL LOBE Consciousness Reasoning Planning Goals Values Sense of Self I NEED TO USE!!!!!!!!!!! FRONTAL LOBE Consciousness Reasoning
More informationGuidelines for the Use of Controlled Substances in the Treatment of Pain Adopted by the New Hampshire Medical Society, July 1998
Guidelines for the Use of Controlled Substances in the Treatment of Pain Adopted by the New Hampshire Medical Society, July 1998 Section I: Preamble The New Hampshire Medical Society believes that principles
More informationFrequently Asked Questions (FAQ s): Medication-Assisted Treatment for Opiate Addiction
Frequently Asked Questions (FAQ s): Medication-Assisted Treatment for Opiate Addiction March 3, 2008 By: David Rinaldo, Ph.D., Managing Partner, The Avisa Group In this FAQ What medications are currently
More informationOTC Abuse. Dr. Eman Said Abd-Elkhalek Lecturer of Pharmacology & Toxicology Faculty of Pharmacy Mansoura University
OTC Abuse Dr. Eman Said Abd-Elkhalek Lecturer of Pharmacology & Toxicology Faculty of Pharmacy Mansoura University Opiates Abuse Opioids are a group of natural, partially synthetic, or synthetic drugs
More informationMAT Counselor Education Course Exam Questions Packet Part 1
MAT Counselor Education Course Exam Questions Packet Part 1 Course No: Course Title: Course Objective: MA-1901P1 Medication-Assisted Treatment (MAT) Counselor Education Course Part 1 Includes primer on
More informationHeroin. How is Heroin Abused? What Other Adverse Effects Does Heroin Have on Health? How Does Heroin Affect the Brain?
Heroin Heroin is a synthetic opiate drug that is highly addictive. It is made from morphine, a naturally occurring substance extracted from the seed pod of the Asian opium poppy plant. Heroin usually appears
More informationFRN Research Report January 2012: Treatment Outcomes for Opiate Addiction at La Paloma
FRN Research Report January 2012: Treatment Outcomes for Opiate Addiction at La Paloma Background A growing opiate abuse epidemic has highlighted the need for effective treatment options. This study documents
More informationHeroin. How Is Heroin Abused? How Does Heroin Affect the Brain? What Other Adverse Effects Does Heroin Have on Health?
Heroin Heroin is an opiate drug that is synthesized from morphine, a naturally occurring substance extracted from the seed pod of the Asian opium poppy plant. Heroin usually appears as a white or brown
More informationNaltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction. Frequently Asked Questions
Naltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction Frequently Asked Questions What is Naltrexone? Naltrexone is a prescription drug that effectively blocks the effects of heroin, alcohol,
More informationConsiderations in Medication Assisted Treatment of Opiate Dependence. Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT
Considerations in Medication Assisted Treatment of Opiate Dependence Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT Disclosures Speaker Panels- None Grant recipient - SAMHSA
More informationAMPHETAMINE AND COCAINE MECHANISMS AND HAZARDS
AMPHETAMINE AND COCAINE MECHANISMS AND HAZARDS BARRY J. EVERITT Department of Experimental Psychology, University of Cambridge Stimulant drugs, such as cocaine and amphetamine, interact directly with dopamine
More information18 Clonidine and Lofexidine: New Nonopiate Treatments for Opiate Withdrawal
INTRODUCTION Recent studies (Gold et al, 1978; Washton et al, 1980a) showing that the non-opiate antihypertensive agent, clonidine hydrochloride, suppresses signs and symptoms of opiate withdrawal, have
More informationSouthlake Psychiatry. Suboxone Contract
Suboxone Contract Thank you for considering Southlake Psychiatry for your Suboxone treatment. Opiate Addiction is a serious condition for which you may find relief with Suboxone treatment. In order to
More informationFACING YOUR FEARS: HOW TO SUCCESSFULLY PERFORM EXPOSURE THERAPY
FACING YOUR FEARS: HOW TO SUCCESSFULLY PERFORM EXPOSURE THERAPY HOW AVOIDANCE FUELS ANXIETY AND HOW EXPOSURE CAN TREAT IT Exposure is the most important behavioural technique that you can use to help you
More informationCLINICAL POLICY Department: Medical Management Document Name: Vivitrol Reference Number: NH.PHAR.96 Effective Date: 03/12
Page: 1 of 7 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationMichigan Guidelines for the Use of Controlled Substances for the Treatment of Pain
Michigan Guidelines for the Use of Controlled Substances for the Treatment of Pain Section I: Preamble The Michigan Boards of Medicine and Osteopathic Medicine & Surgery recognize that principles of quality
More informationIN THE GENERAL ASSEMBLY STATE OF. Ensuring Access to Medication Assisted Treatment Act
IN THE GENERAL ASSEMBLY STATE OF Ensuring Access to Medication Assisted Treatment Act 1 Be it enacted by the People of the State of Assembly:, represented in the General 1 1 1 1 Section 1. Title. This
More informationUse of Vivitrol for Alcohol and Opioid Addiction
Use of Vivitrol for Alcohol and Opioid Addiction Ken Bachrach, Ph.D. Clinical Director, Tarzana Treatment Centers, Inc. kbachrach@tarzanatc.org What is Vivitrol? An injectable from of naltrexone, which
More informationDiscontinuation: Involuntary Discharge
Discontinuation: Involuntary Discharge TYPICALLY A PROCESS NOT AN EVENT Objectives 2 Review indications for discharge. Develop a therapeutic approach, in the context of the nature of Substance Use Disorders.
More informationDeath in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery
Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery Marvin D. Seppala, MD Chief Medical Officer Hazelden Betty Ford Foundation This product is supported by
More informationMedication-Assisted Treatment for Opioid Addiction
Medication-Assisted Treatment for Opioid Addiction This document contains a general discussion of medications approved by the U.S. Food and Drug Administration (FDA) for use in the treatment of opioid
More informationA Multi-Centre Efficacy Trial of Naltrexone Maintenance Therapy in Hong Kong
A Multi-Centre Efficacy Trial of Naltrexone Maintenance Therapy in Hong Kong Executive Summary 1. Study Background 1.1 In May 1999, upon the recommendations of the Action Committee Against Narcotics (ACAN)
More informationHow To Treat A Drug Addiction
1 About drugs Drugs are substances that change a person s physical or mental state. The vast majority of drugs are used to treat medical conditions, both physical and mental. Some, however, are used outside
More informationHulpverleningsmodellen bij opiaatverslaving. Frieda Matthys 6 juni 2013
Hulpverleningsmodellen bij opiaatverslaving Frieda Matthys 6 juni 2013 Prevalence The average prevalence of problem opioid use among adults (15 64) is estimated at 0.41%, the equivalent of 1.4 million
More informationOhio Legislative Service Commission
Ohio Legislative Service Commission Bill Analysis Brian D. Malachowsky H.B. 378 130th General Assembly () Reps. Smith and Sprague BILL SUMMARY Prohibits a physician from prescribing or personally furnishing
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PDP IBT Inj - Vivitrol Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Opiate Antagonist Client: 2007 PDP IBT Inj Approval Date: 2/20/2007
More informationUpdate and Review of Medication Assisted Treatments
Update and Review of Medication Assisted Treatments for Opiate and Alcohol Use Disorders Richard N. Whitney, MD Medical Director Addiction Services Shepherd Hill Newark, Ohio Medication Assisted Treatment
More informationDEVELOPING MANUFACTURING SUPPLYING. Naltrexone Implants. Manufactured by NalPharm Ltd WWW.NALPHARM.COM
DEVELOPING MANUFACTURING SUPPLYING Naltrexone Implants Background to Nalpharm NalPharm is a specialist pharmaceutical company supplying proprietary branded medications and generic drugs in the area of
More informationBehavioural Therapy A GUIDE TO COUNSELLING THERAPIES (DVD) Published by: J & S Garrett Pty Ltd ACN 068 751 440
Behavioural Therapy A GUIDE TO COUNSELLING THERAPIES (DVD) Published by: J & S Garrett Pty Ltd ACN 068 751 440 All Case Histories in this text are presented as examples only and any comparison which might
More informationOffice-based Treatment of Opioid Dependence with Buprenorphine
Office-based Treatment of Opioid Dependence with Buprenorphine David A. Fiellin, M.D Professor of Medicine, Investigative Medicine and Public Health Yale University School of Medicine Dr. Fiellin s Disclosures
More informationHeroin. How Is Heroin Abused? How Does Heroin Affect the Brain? What Other Adverse Effects Does Heroin Have on Health?
Heroin Heroin is an opiate drug that is synthesized from morphine, a naturally occurring substance extracted from the seed pod of the Asian opium poppy plant. Heroin usually appears as a white or brown
More informationUse of Buprenorphine in the Treatment of Opioid Addiction
Use of Buprenorphine in the Treatment of Opioid Addiction Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Executive Summary Which of the following is an
More informationIntroduction to Tolerance, Physical Dependence and Withdrawal
Introduction to Tolerance, Physical Dependence and Withdrawal Carrie G Markgraf, MD, PhD Safety Assessment Merck Research Laboratories 1 Overview Definitions Addiction, psychological dependence, physical
More informationLike cocaine, heroin is a drug that is illegal in some areas of the world. Heroin is highly addictive.
Heroin Introduction Heroin is a powerful drug that affects the brain. People who use it can form a strong addiction. Addiction is when a drug user can t stop taking a drug, even when he or she wants to.
More informationFrequently asked questions
Naltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction Frequently asked questions What is Naltrexone? Naltrexone is a prescription drug that completely blocks the effects of all opioid drugs
More informationWhat is Addiction and How Do We Treat It? Roger D. Weiss, M.D. Professor of Psychiatry, Harvard Medical School Clinical Director, Alcohol and Drug
What is Addiction and How Do We Treat It? Roger D. Weiss, M.D. Professor of Psychiatry, Harvard Medical School Clinical Director, Alcohol and Drug Abuse Treatment Program, McLean Hospital, Belmont, MA
More informationTreatment of opioid use disorders
Treatment of opioid use disorders Gerardo Gonzalez, MD Associate Professor of Psychiatry Director, Division of Addiction Psychiatry Disclosures I have no financial conflicts to disclose I will review evidence
More informationAcute Pain Management in the Opioid Dependent Patient. Maripat Welz-Bosna MSN, CRNP-BC
Acute Pain Management in the Opioid Dependent Patient Maripat Welz-Bosna MSN, CRNP-BC Relieving Pain in America (IOM) More then 116 Million Americans have pain the persists for weeks to years $560-635
More information02 DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION
Effective June 13, 2010 02-313, 02-373, 02-380, 02-383, 02-396 Chapter 21 page 1 02 DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION 313 BOARD OF DENTAL EXAMINERS 373 BOARD OF LICENSURE IN MEDICINE
More informationPolicy #: 457 Latest Review Date: December 2010
Effective for dates of service on or after January 1, 2015 refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm Name of Policy: Naltrexone (Vivitrol ) Injections Policy #: 457 Latest Review
More informationMEDICALLY SUPERVISED OPIATE WITHDRAWAL FOR THE DEPENDENT PATIENT. An Outpatient Model
MEDICALLY SUPERVISED OPIATE WITHDRAWAL FOR THE DEPENDENT PATIENT An Outpatient Model OBJECTIVE TO PRESENT A PROTOCOL FOR THE EVALUATION AND TREATMENT OF PATIENTS WHO ARE CHEMICALLY DEPENDENT ON OR SEVERLY
More informationPatients are still addicted Buprenorphine is simply a substitute for heroin or
BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals Module VI: Myths About the Use of Medication in Recovery Patients are still addicted Buprenorphine is simply a substitute
More informationOne example: Chapman and Huygens, 1988, British Journal of Addiction
This is a fact in the treatment of alcohol and drug abuse: Patients who do well in treatment do well in any treatment and patients who do badly in treatment do badly in any treatment. One example: Chapman
More informationChapter 9: Drug Abuse and Addiction
Chapter 9: Drug Abuse and Addiction Drug use and abuse- some history Drug addiction: Defining terms Physical dependence/ drug withdrawal Factors that influence development and maintenance of drug addiction
More informationEPIDEMIOLOGY OF OPIATE USE
Opiate Dependence EPIDEMIOLOGY OF OPIATE USE Difficult to estimate true extent of opiate dependence Based on National Survey of Health and Mental Well Being: 1.2% sample used opiates in last 12 months
More informationA G U I D E F O R U S E R S N a l t r e x o n e U
A GUIDE FOR USERS UNaltrexone abstinence not using a particular drug; being drug-free. opioid antagonist a drug which blocks the effects of opioid drugs. dependence the drug has become central to a person
More informationProgrammed Learning Review
Programmed Learning Review L-HO1-121907 Take another sheet of paper and cover the answers located in the right hand column. Then read through the unit filling in the blanks as you go. After filling in
More informationMedications for Alcohol and Drug Dependence Treatment
Medications for Alcohol and Drug Dependence Treatment Robert P. Schwartz, M.D. Medical Director Rschwartz@friendsresearch.org Friends Research Institute Medications for Alcohol Dependence Treatment Disulfiram
More informationIn 2010, approximately 8 million Americans 18 years and older were dependent on alcohol.
Vivitrol Pilot Study: SEMCA/Treatment Providers Collaborative Efforts with the treatment of Opioid Dependent Clients Hakeem Lumumba, PhD, CAADC SEMCA Scott Schadel, MSW, LMSW, CAADC HEGIRA PROGRAMS, INC.
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2011 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationTreatment and Interventions for Opioid Addictions: Challenges From the Medical Director s Perspective
Treatment and Interventions for Opioid Addictions: Challenges From the Medical Director s Perspective Dale K. Adair, MD Medical Director/Chief Psychiatric Officer OMHSAS 1 Treatment and Interventions for
More informationMedications Used in the Treatment of Addiction Developed by Randall Webber, MPH. Alcohol Withdrawal
Medications Used in the Treatment of Addiction Developed by Randall Webber, MPH Alcohol Withdrawal MEDICATION Long/intermediateacting benzodiazepines (e.g., chlordiazepoxide/ Librium, diazepam/valium)
More informationFactors Influencing the Effectiveness of Substance Abuse Treatments
Factors Influencing the Effectiveness of Substance Abuse Treatments Stephen Jurd Area Medical Director Drug and Alcohol Services Northern Sydney Health Patient Factors Social Stability - education, marital
More informationScientific Facts on. Psychoactive Drugs. Tobacco, Alcohol, and Illicit Substances
page 1/5 Scientific Facts on Psychoactive Drugs Tobacco, Alcohol, and Illicit Substances Source document: WHO (2004) Summary & Details: GreenFacts Context - Psychoactive drugs such as tobacco, alcohol,
More informationUCLA-SAPC Lecture Series March 13, 2015. Gary Tsai, M.D. Medical Director Substance Abuse Prevention and Control
UCLA-SAPC Lecture Series March 13, 2015 Gary Tsai, M.D. Medical Director Substance Abuse Prevention and Control Neurobiology 101 Neuroscience of Addiction & Recovery Medication-Assisted Treatment (MAT)
More informationfmri studies of addiction and relapse Rebecca Elliott Bill Deakin Anna Murphy Neuroscience and Psychiatry Unit
fmri studies of addiction and relapse Rebecca Elliott Bill Deakin Anna Murphy Neuroscience and Psychiatry Unit Background Previous PhD projects on brain basis of craving: Lesley Peters and Dan Lubman Expertise
More informationHAWAII BOARD OF MEDICAL EXAMINERS PAIN MANAGEMENT GUIDELINES
Pursuant to section 453-1.5, Hawaii Revised Statutes, the Board of Medical Examiners ("Board") has established guidelines for physicians with respect to the care and treatment of patients with severe acute
More informationKaiser Permanente Department of Addiction Medicine Panel May 21, 2010
Youth and Opiates Kaiser Permanente Department of Addiction Medicine Panel May 21, 2010 Panel Members Dr. Brad Anderson Kathy Tomlin Jeff Beatty Phil Anderson Panel Program Introduce to KP-AM Suboxone
More informationNora D. Volkow, M.D. Director National Institute on Drug Abuse
Nora D. Volkow, M.D. Director National Institute on Drug Abuse Medications Currently Available For Nicotine Addiction Nicotine Replacement Therapies (NRT) Bupropion Varenicline For Alcoholism Disulfiram
More informationOpioid Addiction & Methadone Maintenance Treatment. What is Methadone? What is an Opioid?
Opioid Addiction & Methadone Maintenance Treatment Dr. Nick Wong MD, CCFP AADAC Edmonton ODP AADAC AHMB Concurrent Disorder Series September 13, 2007 1 What is Methadone? What is methadone? Synthetic opioid.
More informationNon medical use of prescription medicines existing WHO advice
Non medical use of prescription medicines existing WHO advice Nicolas Clark Management of Substance Abuse Team WHO, Geneva Vienna, June 2010 clarkn@who.int Medical and Pharmaceutical role Recommendations
More informationMEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION
MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION Mark Fisher Program Administrator State Opioid Treatment Adminstrator Kentucky Division of Behavioral Health OBJECTIVES Learn about types of opioids and
More informationAlcohol Overuse and Abuse
Alcohol Overuse and Abuse ACLI Medical Section CME Meeting February 23, 2015 Daniel Z. Lieberman, MD Professor and Vice Chair Department of Psychiatry George Washington University Alcohol OVERVIEW Definitions
More informationOpioid/Opiate Dependent Pregnant Women
Opioid/Opiate Dependent Pregnant Women The epidemic, safety, stigma, and how to help. Presented by Lisa Ramirez MA,LCDC & Kerby Stewart MD The prescription painkiller epidemic is killing more women than
More informationMOBC Research Highlights Reel. Mitch Karno Mechanisms of Behavior Change Conference San Antonio, Texas June 20, 2015
MOBC Research Highlights Reel Mitch Karno Mechanisms of Behavior Change Conference San Antonio, Texas June 20, 2015 Starring -Change Talk -Attentional Bias -Self-Efficacy -Social Network -Craving Study
More informationApplicant Webinar for BJA s Drug Court Discretionary Grant Solicitation
Applicant Webinar for BJA s Drug Court Discretionary Grant Solicitation Cynthia Caporizzo, Senior Criminal Justice Advisor, Office of National Drug Control Policy (ONDCP) - Review of the administration
More informationOVERVIEW OF MEDICATION ASSISTED TREATMENT
Sarah Akerman MD Assistant Professor of Psychiatry Director of Addiction Services Geisel School of Medicine/Dartmouth-Hitchcock Medical Center OVERVIEW OF MEDICATION ASSISTED TREATMENT Conflicts of Interest
More informationCo occuring Antisocial Personality Disorder and Substance Use Disorder: Treatment Interventions Joleen M. Haase
Co occuring Antisocial Personality Disorder and Substance Use Disorder: Treatment Interventions Joleen M. Haase Abstract: Substance abuse is highly prevalent among individuals with a personality disorder
More informationLESSON 5.7 WORKBOOK Is addiction a chronic disease?
DEFINITIONS OF TERMS Addiction is a disease idea that states drug addiction is no different from other chronic diseases, like diabetes and heart disease, and thus needs to be treated as a distinct medical
More informationAddictions. Assessment
Addictions Assessment What is Addiction?..a degree of involvement in a behaviour that can function both to produce pleasure and to provide relief from discomfort, to the point where the costs appear to
More informationOpioid Dependence: A Chronic, Relapsing Brain Disease
Opioid Dependence: A Chronic, Relapsing Brain Disease Presentation Objectives Review the evidence that opioid dependence is a chronic, relapsing disease Demonstrate similarities of opioid dependence to
More informationPain, Addiction & Methadone
Pain, Addiction & Methadone A CHALLENGING INTERFACE METHADONE AND SUBOXONE OPIOID SUBSTITUTION CONFERENCE Objectives 2 Explore the interface between concurrent pain and addiction. Appreciate the challenges
More informationPainkiller addiction and pseudoaddiction in SCD (presentation 2 in a series of 3)
Painkiller addiction and pseudoaddiction in SCD (presentation 2 in a series of 3) James Elander University of Derby j.elander@derby.ac.uk http://psychology.derby.ac.uk/staff/james_elander.html SCOOTER
More informationOpioids Research to Practice
Opioids Research to Practice CRIT/FIT 2015 May 2015 Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Assistant Dean, Continuing Medical Education Director, Clinical Addiction Research
More informationOpioid Treatment Services, Office-Based Opioid Treatment
Optum 1 By United Behavioral Health U.S. Behavioral Health Plan, California Doing Business as OptumHealth Behavioral Solutions of California ( OHBS-CA ) 2015 Level of Care Guidelines Opioid Treatment Services,
More informationNeurobiology and Treatment of Alcohol Dependence. Nebraska MAT Training September 29, 2011
Neurobiology and Treatment of Alcohol Dependence Nebraska MAT Training September 29, 2011 Prior treatment episodes for persons starting treatment for alcohol dependence, 2009 Percent 50 45 40 35 30 25
More informationCONTINGENCY MANAGEMENT AND ANTISOCIAL PERSONALITY DISORDER
CONTINGENCY MANAGEMENT AND ANTISOCIAL PERSONALITY DISORDER Karen K. Chan 1,3, Alice Huber 1,2,3, John M. Roll 1,3, and Vikas Gulati 1,3 Friends Research Institute, Inc. 1 Long Beach Research Foundation:
More informationHEROIN AND RELATED OPIATES
HEROIN AND RELATED OPIATES DAVID J. NUTT Psychopharmacology Unit, Bristol University Heroin is a derivative of morphine and both belong to a large family of drugs called the opiates, that were originally
More informationThe Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office
The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office Adopted April 2013 for Consideration by State Medical Boards 2002 FSMB Model Guidelines
More informationSubstitution Therapy for Opioid Dependence The Role of Suboxone. Mandy Manak, MD, ABAM, CCSAM Methadone 101-Hospitalist Workshop, October 3, 2015
Substitution Therapy for Opioid Dependence The Role of Suboxone Mandy Manak, MD, ABAM, CCSAM Methadone 101-Hospitalist Workshop, October 3, 2015 Objectives Recognize the options available in treating opioid
More informationSUBSTANCE USE DISORDER SOCIAL DETOXIFICATION SERVICES [ASAM LEVEL III.2-D]
SUBSTANCE USE DISORDER SOCIAL DETOXIFICATION SERVICES [ASAM LEVEL III.2-D] I. Definitions: Detoxification is the process of interrupting the momentum of compulsive drug and/or alcohol use in an individual
More informationObservational study of the long-term efficacy of ibogaine-assisted therapy in participants with opioid addiction STUDY PROTOCOL
Observational study of the long-term efficacy of ibogaine-assisted therapy in participants with opioid addiction Purpose and Objectives STUDY PROTOCOL This research is an investigator-sponsored observational
More informationCURRICULUM VITAE. 223 Arroyo Grande Way Santa Clara University Los Gatos, CA 95032 Santa Clara, CA 95053 (408) 358-3092 (408) 554-4347
CURRICULUM VITAE Robert Numan Department of Psychology 223 Arroyo Grande Way Santa Clara University Los Gatos, CA 95032 Santa Clara, CA 95053 (408) 358-3092 (408) 554-4347 EDUCATION Ph.D. B.S. University
More information